Back
 

View:
Mini 
BasicThis view is available after user registration.
 
ShortThis view is available when you buy a license.
 
StandardThis view is available when you buy a license.
 
CompleteThis view is available when you buy a license.
 

Enfortumab Vedotin 1.25 / Pembrolizumab 200, Bladder Cancer

Protocol-ID: 2366 V1.1 (Mini), ENFVED1.25/PEMB200, Bladder Cancer

Indication(s)

  • Bladder Cancer; ICD-10 C67.-

Links

  • LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC) T.B. Powles B. Perez Valderrama S. Gupta X. Yu S. Gorla B.M.S. Homet Moreno van der Heijden ABSTRACT| VOLUME 34, SUPPLEMENT 2, S1340, OCTOBER 2023 [DOI]
The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 22.03.2024